HIF1A and neoplasm: Verheul et al., demonstrated in prostate and renal cancer cell lines that combination treatment with the mTOR inhibitor rapamycin and the HDAC inhibitor LBH589, significantly reduced HIF-1α protein expression and consequently suppressed tumour induced angiogenesis on comparison with either agent used singularly [69].